Axsome Therapeutics (AXSM) EBIT (2015 - 2026)

Axsome Therapeutics has disclosed EBIT across 12 years of filings, most recently posting -$63.4 million for Q1 2026.

• EBIT for Q1 2026 came in at -$63.4 million, down 11.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.9 million (up 83.4% YoY), and the FY2025 annual result was -$38.5 million, up 86.29% from the prior year.
• EBIT came in at -$63.4 million for Q1 2026 at Axsome Therapeutics, down from $101.3 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $101.3 million in Q4 2025 to a low of -$98.3 million in Q4 2023.
• The 5-year median for EBIT is -$59.9 million (2022), against an average of -$46.7 million.
• Across the five-year window, EBIT tumbled 955.46% in 2024 and soared 239.53% in 2025, its largest moves.
• Axsome Therapeutics' EBIT stood at -$59.9 million in 2022, then plunged by 64.01% to -$98.3 million in 2023, then advanced by 26.11% to -$72.6 million in 2024, then jumped by 239.53% to $101.3 million in 2025, then plunged by 162.53% to -$63.4 million in 2026.
• The last three EBIT figures came in at -$63.4 million (Q1 2026), $101.3 million (Q4 2025), and -$46.1 million (Q3 2025), per Business Quant data.